Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
KDM4A is a member of the Jumonji domain 2 (JMJD2) family and encodes a protein containing a JmjN domain, a JmjC domain, a JD2H domain, two TUDOR domains, and two PHD-type zinc fingers. Additionally we are shipping KDM4A Antibodies (121) and KDM4A Proteins (5) and many more products for this protein.
Showing 2 out of 5 products:
These results reveal KDM4A as a key epigenetic silencer of TRAIL and DR5 (show TNFRSF10B ELISA Kits) in tumors.
Findings inidicate a unique breast cancer stem-like cells (BCSC) culture system for drug screening and offer preclinical proof of concept for lysine demethylase (show MBD2 ELISA Kits) 4A (KDM4A) inhibition as a new strategy to treat triple-negative breast cancer.
The pyruvate dehydrogenase (show PDP ELISA Kits) kinases (PDKs) PDK1 (show PDK1 ELISA Kits) and PDK3 (show PDK3 ELISA Kits) are direct targets of KDM4A and E2F1 (show E2F1 ELISA Kits) and modulate the switch between glycolytic metabolism and mitochondrial oxidation.
results suggest that KDM4A possesses the potential to act as an oxygen sensor in the context of chromatin modifications, with possible implications for epigenetic regulation in hypoxic disease states
Here we show that JMJD2A, the first identified Jumonji (show JARID2 ELISA Kits) C domain-containing histone demethylase (show MBD2 ELISA Kits), is the histone demethylase (show MBD2 ELISA Kits) responsible for SUMO-2 (show SUMO2 ELISA Kits)/3 enrichment on the Kaposi's sarcoma associated herpesvirus genome during viral reactivation
Lgr4 activates Jmjd2a/AR signaling pathway to promote interaction AR with PSA promoter, causing reduction of prostate cancer apoptosis and cell cycle arrest.
We demonstrate the previously unreported inhibitory action of PKF118-310 on KDM4A. Our findings open up the possibility of developing the first KDM4A-specific inhibitors and derivatives.
KDM4A downregulation promotes autophagy in glioma cell lines.
ERG (show ERG ELISA Kits) promotes prostate tumorigenesis together with KDM4A through the upregulation of YAP1 (show YAP1 ELISA Kits). A corollary is that KDM4A as well as YAP1 (show YAP1 ELISA Kits) inhibitors may prove beneficial for the therapy of ERG (show ERG ELISA Kits)-overexpressing prostate tumors.
In pancreatic neoplasms, miR (show MLXIP ELISA Kits)-137 targets KDM4A mRNA during Ras-induced senescence and activates both p53 (show TP53 ELISA Kits) and retinoblastoma (pRb (show RB1 ELISA Kits)) tumor suppressor pathways.
High Jmjd2a expression is associated with neuropathic pain.
This study dissects an important dual role for maternal Kdm4a in determining faithful early embryonic development and the implantation process.
We propose the inhibition of KDM4A activity as a strategy to suppress IL-6 (show IL6 ELISA Kits) production and attenuate colitis induction.
The authors show that Jmjd2a and Jmjd2c (show KDM4C ELISA Kits) both localize to H3K4me3-positive promoters, where they have widespread and redundant roles in preventing accumulation of H3K9me3 and H3K36me3.
these data reveal a JMJD2A/ETV1 (show ETV1 ELISA Kits)/YAP1 (show YAP1 ELISA Kits) axis that promotes prostate cancer initiation and that may be a suitable target for therapeutic inhibition.
Results indicate that SCF (show KITLG ELISA Kits)(Fbxo22 (show FBXO22 ELISA Kits))-KDM4A is an E3 ubiquitin ligase that targets methylated p53 (show TP53 ELISA Kits) and regulates key senescent processes.
These findings together demonstrate the essential role of KDM4A and KDM4C (show KDM4C ELISA Kits) in orchestrating mESC differentiation to endothelial cells through the activation of Flk1 (show KDR ELISA Kits) and VE-cadherin (show CDH5 ELISA Kits) promoters, respectively
As well as three novel motifs in JMJD2A-regulated genes.
JMJD2A bound to the FHL1 (show FHL1 ELISA Kits) promoter in response to TAC (show IL2RA ELISA Kits), upregulated FHL1 (show FHL1 ELISA Kits) expression, and downregulated H3K9 trimethylation. JMJD2A promotes cardiac hypertrophy under pathological conditions by a novel mechanism.
JHDM3A(GFP)(701) is a suitable catalytic module that can be targeted, under the control of a guide protein, to specific loci where the chromatin H3K9me3 status and the milieu of gene expression are to be modified.
Histone demethylases KDM3A, KDM4A, and KDM4C were expressed before and after embryonic genome activation, whereas KDM5B was mainly expressed during the blastocyst period.
This gene is a member of the Jumonji domain 2 (JMJD2) family and encodes a protein containing a JmjN domain, a JmjC domain, a JD2H domain, two TUDOR domains, and two PHD-type zinc fingers. This nuclear protein functions as a trimethylation-specific demethylase, converting specific trimethylated histone residues to the dimethylated form, and as a transcriptional repressor.
jumonji domain containing 2A
, lysine (K)-specific demethylase 4A
, lysine-specific demethylase 4A
, jumonji domain-containing protein 2A
, JmjC domain-containing histone demethylation protein 3A
, jumonji domain-containing 2A
, lysine-specific demethylase 4A-like
, jmjC domain-containing histone demethylation protein 3A
, jumonji C domain-containing histone demethylase 3A
, jumonji domain containing 2
, tudor domain containing 14A